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A 55-year-old man with a history of erosive, seropositive rheumatoid arthritis (RA), and 
interstitial lung disease presented with shortness of breath. Echocardiography showed 
new-onset severe left ventricular (LV) dysfunction with an ejection fraction (EF) of 15% and 
moderately increased mean aortic valve gradient of 20 mmHg in a trileaflet aortic valve 
with severe sclero-calcific degeneration. Coronary angiography revealed no significant 
obstructive coronary disease. Invasive hemodynamic studies and dobutamine stress 
echocardiography were consistent with moderate aortic stenosis. Guideline directed 
medical therapy for heart failure with reduced EF was initiated; however, diuretics and 
neurohormonal blockade (beta-blocker and angiotensin receptor blocker) provided min-
imal improvement, and the patient remained functionally limited. Of interest, echocardi-
ography performed 1 year prior to his presentation showed normal LV EF and mild aortic 
leaflet calcification with moderate stenosis, suggesting a rapid progressing of calcific 
aortic valve disease. Subsequently, the patient underwent surgical aortic valve replace-
ment and demonstrated excellent postsurgical recovery of LV EF (55%). Calcific aortic 
valve disease is commonly associated with aging, bicuspid aortic valve, and chronic 
kidney disease. Pathophysiological mechanism for valvular calcification is incompletely 
understood but include osteogenic transformation of valvular interstitial cells mediated 
by local and systemic inflammatory processes. Several rheumatologic diseases includ-
ing RA are associated with premature atherosclerosis and arterial calcification, and we 
speculated a similar role of RA accelerating calcific aortic valve disease. We present a 
case of accelerated aortic valve calcification with (only) moderate stenosis, complicated 
by a rapid decline in LV systolic performance. Guidelines for AVR in moderate stenosis 
without concomitant cardiac surgery are not well established, although it should be 
considered in selected patients.
Keywords: calcific aortic valve disease, aortic stenosis, aortic valve replacement, rheumatoid arthritis, heart 
failure
tabLe 1 | serial measurements of pro-bNp.
Date pro-bNp (reference range 
<125 pg/mL)
03/2014 63
12/2014 234
03/2015 548
04/2015 852
11/2015 1,520
11/2015 1,829
12/2015 1,027
03/2016 2,035
→7/2016 surgical aortic valve replacement
11/2016 239
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INtRoDUCtIoN
A 55-year-old man with a medical history significant for erosive, 
seropositive rheumatoid arthritis (RA), and interstitial lung dis-
ease (ILD) was hospitalized for shortness of breath and bilateral 
foot pain over the past 3 weeks. He described worsening pain in 
the bilateral medial malleoli and both great toes similar to pain 
he had in the past related to his diagnosis of RA. He described 
becoming more dyspneic on exertion than his baseline, for which 
he required supplemental oxygen. Initial vital signs on presenta-
tion were as followed: blood pressure of 146/106 mmHg, heart rate 
124 beats per minute and regular, respiratory rate of 28 breaths per 
minute, body mass index 34.5 kg/m2, and pulse oximetry was 92% 
on 3 L supplemental oxygen by nasal cannula. The patient was 
alert and had mild respiratory distress on presentation. Cardiac 
examination was notable for a soft systolic murmur on the left 
sternal border, jugular venous distension to 15  mmHg above 
the clavicle, and fine inspiratory crackles at the bases of both 
lungs. Skin was warm to touch with 2+ lower extremity edema 
bilaterally from the mid-shin downward. Initial laboratory values 
were notable for sodium of 133 mmol/L, potassium 4 mmol/L, 
creatinine 1.3  mg/dL, and an elevated N-terminal pro b-type 
natriuretic peptide of 1,829 pg/mL (Table 1). LDL was 119 mg/
dL, HDL 56 mg/dL, trigylcerides 166 mg/dL, glucose 91 mg/dL, 
and HbA1c 5.5%. White blood cell count and hemoglobin were 
within normal limits at 6.3 × 103/μL and 15.7 g/dL, respectively. 
The electrocardiogram showed sinus tachycardia, and no ST and T 
wave changes, concerning for acute ischemia. Prior to admission, 
medications included albuterol-ipratroprium 18–103 μg 2 puffs 
four times per day, carvedilol 6.25  mg twice a day, famotidine 
20  mg twice a day, furosemide 20  mg once daily, certolizumab 
injection once per month, and hydroxychloroquine 200 mg twice 
a day.
Chest X-ray revealed moderate cardiomegaly with bibasilar 
consolidations and moderate pulmonary edema with small 
pleural effusions bilaterally. Bilateral foot X-rays revealed chronic 
erosions at the head of the left great toe and mild soft tissue swell-
ing and a chronic appearing erosion of the proximal phalanx of 
the right great toe, both unchanged from prior study. His foot 
pain responded to analgesics.
The clinical presentation was suggestive of acute decompen-
sated heart failure. This was confirmed with the transthoracic 
echocardiogram that demonstrated severely decreased left 
ventricular (LV) function with an ejection fraction (EF) of 
10–15%, moderate mitral regurgitation, severe right ventricular 
dysfunction, and severe tricuspid regurgitation. The severity of AS 
could not be assessed due to image acquisition quality. Of note, an 
echocardiogram performed 11 months earlier had a normal EF of 
55%, mild LV hypertrophy, normal right ventricular performance 
and size, moderate aortic valve sclero-calcific changes with a 
mean systolic trans-aortic gradient of 20 mmHg, and a calculated 
aortic valve area by continuity equation of 1.2 cm2, consistent with 
moderate AS. No other valvular lesions were present at that time.
For further evaluation of possible underlying causes for the 
new onset of biventricular dysfunction, a cardiac magnetic reso-
nance imaging with vasodilator stress and gadolinium contrast 
was performed. Late gadolinium enhancement was present in 
the basal and mid-ventricular septum in a pattern consistent 
with a dilated cardiomyopathy and not a myocardial infarction. 
No perfusion defects were noticed. Further workup revealed 
distal segmental right lower lobe pulmonary embolus and he was 
appropriately started on rivaroxaban for pulmonary embolus. 
Other medical therapy for decompensated heart failure included 
diuresis with intravenous furosemide, followed with transition to 
discharge medication including lisinopril 20 mg daily, spironol-
actone 25 mg daily, carvedilol XL 25 mg daily, and furosemide 
40 mg daily. A 4-day course of prednisone 10 mg was added in 
addition to home hydroxylchlorquine 200 mg twice daily for his 
history of RA. Furthermore, certolizumab doses were held due to 
development of heart failure.
The patient’s heart failure was medically optimized in follow-
up consultations in our outpatient cardiology clinic, though he 
continued to demonstrate New York Heart Association Class III 
symptoms despite up-titration of goal-directed therapies of beta-
blockers, angiotensin-converting enzyme inhibitors, aldosterone 
antagonists, and diuretics. It was postulated that his RA-related 
ILD, arterial hypertension, as well as suboptimal compliance with 
medications and diet were contributing to his ongoing dyspnea 
with minimal exertion.
Four months following his initial hospitalization and diagno-
sis of biventricular dysfunction and pulmonary embolism, the 
patient was re-hospitalized and admitted to the cardiac intensive 
care unit with respiratory distress requiring non-invasive positive 
pressure ventilation. Respiratory panel testing during workup 
revealed positive testing for Influenza A virus. He was treated 
with oseltamivir and briefly required inotropic therapy in addi-
tion to continuous furosemide infusion. Repeat echocardiogram 
showed again severely reduced EF (<20%) now with qualitatively 
severe calcific changes of the aortic valve with a mean gradient 
of 17 mmHg and an aortic valve area of 0.83 cm2. EKG showed 
sinus tachycardia at 123 bpm but was otherwise unremarkable. 
Right and left heart catheterization was performed for further 
evaluation of cardiogenic shock. Coronary angiogram revealed 
no significant obstructive coronary artery disease. Invasive hemo-
dynamic measurements during right and left heart catheteriza-
tion demonstrated increased biventricular filling pressures (RA 
12 mmHg, RV 52/12 mmHg, PA 50/30 with mean of 23 mmHg, 
and LVEDP 30 mmHg), mildly reduced cardiac output (PA satu-
ration 73%, cardiac index by Fick 2.9 L/min, and cardiac index 
by thermodilution 2.6 L/min), and moderate aortic stenosis with 
tabLe 2 | Diagnostic testing in evaluation of aortic stenosis.
test Interpretation of the study Mean transaortic gradient 
(mmHg) and aortic valve 
area (cm2)
ejection fraction 
(%)
06/2013 •	 Moderate sclerocalcific changes
•	 No AS, no AI
49
Echocardiography
03/2014 •	 Moderate sclerocalcific changes •	 11 mmHg
•	 1.6 cm2
53
Echocardiography
12/2014 •	 Moderate sclerocalcific changes
•	 Mild-moderate AS
•	 19.5 mmHg
•	 1.2 cm2
55
Echocardiography
11/2015 •	  Aortic stenosis, the severity of which cannot be accurately evaluated in 
the presence of such profound left ventricular (LV) systolic dysfunction
10–15
Echocardiography
First presentation for new-onset heart 
failure
03/2016 •	 Technically difficult study
•	 LV moderately severe reduced
•	 Severe sclerocalcific changes
•	 16.6 mmHg
•	 0.83 cm2Echocardiography
Presentation in cardiogenic shock, 
influenza A virus
03/2016 •	 Moderate AS
•	 Biventricular elevated filling pressures
•	 No obstructive CAD
•	  LV/Aorta peak-to-peak 
gradient: 20 mmHg
•	 1.5 cm2
LHC and RHC
Presentation in cardiogenic shock, 
influenza A virus
05/2016
Dobutamine stress ECHO
•	 Good contractile reserve
•	 Fixed moderate AS
•	  Baseline global hypokinesis with augmentation of all segments with stress
Gradient: 12 mmHg and 
increase to 19 mmHg
25 and increase 
to 43 
Area: 1.37/1.36 cm2
7/2016 •	  Severe aortic sclerosis with preserved leaflet opening. There is moderate 
aortic stenosis. There is trace aortic regurgitation.TEE-intraoperative during AVR
7/2016 •	 Bioprosthetic AVR
•	 Normal LV function
50–55
ECHO, POD 4
Patient had several echocardiograms performed between 2010 and 2016 due to his interstitial lung disease and chronic shortness of breath.
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peak-to-peak pressure gradient of 20 mmHg between left ventricle 
and ascending aorta, with a calculated aortic valve area of 1.5 cm2 
by the Hakki equation (1). The patient subsequently recovered 
from cardiogenic shock exacerbated by influenza A virus and was 
discharged from the hospital on medical therapy with low doses of 
metoprolol, lisinopril, and furosemide. In addition, he was contin-
ued on anticoagulation for his previously diagnosed subsegmental 
pulmonary embolus and hydroxychloroquine for RA.
The next encounter was 3  weeks later in the outpatient 
cardiology clinic when the patient presented in compensated 
and stable chronic heart failure NYHA class III. He was in no 
distress, normotensive with some findings consistent with heart 
failure including elevated jugular vein distension 10  cm above 
the clavicle, fine inspiratory crackles bilaterally, and 1+ edema 
bilateral above the ankle. A dobutamine stress echocardiogram 
was performed to further characterize the severity of calcific 
aortic valve disease. With dobutamine (20 μg/kg/min), the visual 
estimated EF increased from 25 to 43%, and this was associated 
with a change of mean baseline aortic gradient of 12–19 mmHg, 
with a calculated aortic valve area by the continuity equation of 
1.37 cm2. These findings are consistent with moderately severe 
aortic stenosis and moderate LV dysfunction with good contrac-
tile reserve. Given the patient’s ongoing dyspnea and functional 
limitations, which had progressed over a year, along with new 
LV dysfunction without alternate cause, referral for aortic valve 
replacement was made. His case was discussed in an interdisci-
plinary colloquium including general cardiology, rheumatology, 
pulmonology, interventional cardiology, and cardiothoracic 
surgery. CT-chest and pulmonary function testing were obtained 
for preoperative risk stratification. The results of the pulmonary 
function testing were as follows: TLC 3.81 L (=57% of predicted), 
FVC 1.88  L (=42% of predicted), FEV1 1.55  L (=48% of pre-
dicted), FEV1/FVC 82% (=114% of predicted), and DLCO 8.78 
(=32% of predicted) and were interpreted as moderately severe 
restrictive lung disease with a disproportionate reduction in 
diffusing capacity. The patient subsequently underwent surgical 
AVR with a 27-mm bioprosthetic aortic valve and tricuspid valve 
annuloplasty repair, and the initial post-op recovery was excellent. 
Patient’s echocardiogram post aortic valve replacement revealed 
recovery of EF to 55% (Table 2). However, on postoperative day 7, 
he developed signs of decreased end-organ perfusion and was 
found to have pericardial tamponade for which he underwent 
a pericardial window procedure, which drained 360  mL blood 
from the pericardium. There were no other complications, and 
patient was discharged to subacute rehabilitation facility 12 days 
after cardiac surgery. He was seen 6 weeks later in the cardiology 
clinic and was found to be in atrial flutter with 2:1 conduction and 
a heart rate of 126 bpm. This was associated with only minimal 
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symptoms of slightly increased dyspnea on excertion. He under-
went DC cardioversion and has been doing very well since then 
with documented sinus rhythm 2 and 3 months later.
DIsCUssIoN
Aortic valve disorders are the most common valvular lesions 
requiring surgical intervention. Aortic valve replacement is 
commonly utilized for symptomatic patients with severe aortic 
stenosis. In the setting of aortic stenosis, maintenance of LV sys-
tolic function is achieved by a compensatory increase in LV wall 
thickness to balance the pressure overload from the obstructive 
valvular lesion. As the degree of valvular obstruction progresses, 
the compensatory mechanism of LV hypertrophy is overwhelmed 
by the underlying wall stress, and LV dilation and a fall in EF, 
along with the development of symptoms, occur (2). We speculate 
that in patients with underlying subclinical cardiomyopathies, 
compensatory mechanisms will be overwhelmed at even less than 
severe AS. However, the role of AVR in symptomatic patients with 
moderate AS is controversial, and selection of the best approach 
remains clinically challenging usually due to the presence of 
multiple confounding comorbidities (3). The role for AVR in 
documented low-flow, low-gradient aortic stenosis, classified as 
moderate in severity is not well defined (4). The current case is an 
example of aortic stenosis consistently characterized as “moder-
ate AS” by echocardiography and invasive hemodynamics, but 
also with accelerated calcification of the aortic valve leaflets and 
rapid decline of LV function. We have stepwise documentation of 
rapidly declining LV systolic function from a normal EF to one 
of 15% within 1 year. The underlying mechanisms leading to the 
encountered severe LV dysfunction are likely multifactorial and 
possibly include increased afterload from moderate aortic steno-
sis, along with potential some cardiotoxic side effects of conven-
tional and biologic disease modifying antirheumatic medications, 
although this is controversial (5, 6). Importantly, the profound LV 
dysfunction was completely reversed within days of valve replace-
ment emphasizing the significant role of afterload reduction for 
the treatment of a failing left ventricle, which is commonly seen 
in patients with severe AS and LV dysfunction (7, 8).
Among patients with a failing left ventricle, relief of a fixed after-
load reduction in the form of significant aortic stenosis may result 
in the greatest long-term survival benefit. The current American 
Heart Association valvular heart disease guidelines give a Grade 
IIb recommendation stating that it is reasonable to perform aortic 
valve replacement for moderate AS in patients who are undergoing 
other cardiac surgeries. There are no guideline recommendations to 
guide treatment of symptomatic patients with reduced LV systolic 
function and moderate AS. However, a contemporary study by 
Samad and colleagues sought to assess the effect of AVR with and 
without coronary artery bypass surgery and survival in patients 
with moderate and severe AS. Of the 1,634 patients included in this 
retrospective single-center analysis, 1,090 of those were classified 
as moderate by valve area of >1 cm2 and mean gradient range of 
25–39  mmHg. In a subgroup of those who underwent surgical 
AVR with a diagnosis of moderate AS, 135 underwent isolated 
AVR, while 152 had AVR plus coronary artery bypass surgery. In 
135 patients who only had AVR, valve replacement within 90 days 
of index echocardiogram in the setting of moderate aortic stenosis 
and LV dysfunction (defined as <50%, 108 patients with EF<35%) 
conferred a significant long-term mortality benefit of 42% com-
pared to those who did not undergo surgery (9). Although this 
was not a randomized clinical trial, the data suggest that AVR for 
moderate AS with LV dysfunction resulted in superior outcome 
over medical therapy in selected patients. Prior detriments to 
referring patients with symptomatic AS for valve replacement may 
include advanced age with short life expectancy, LV dysfunction, 
lung disease, and renal disease (10, 11). These data suggest that in 
the setting of LV dysfunction with moderate AS, as a contribu-
tor or bystander condition, relief of the hemodynamic burden of 
additional afterload likely contributes a significant survival benefit 
in selected patients. In the last decade, transcatheter aortic valve 
replacement (TAVR) has become the preferred treatment option 
for patients with severe AS and high operative risk (12). Recent 
trial data have even suggested that TAVR is non-inferior to surgical 
AVR in patients in intermediate-risk severe AS (13). Coexisting 
moderate AS and LV systolic dysfunction is not uncommon, and 
now with the advent of TAVR, upcoming clinical trials will seek 
to address whether a less invasive approach such as TAVR may be 
a viable strategy to reduce afterload in patient’s with LV systolic 
dysfunction and concomitant moderate aortic stenosis, who are of 
high surgical risk (14).
Our patient did not have baseline chronic kidney disease, 
diabetes, abnormalities in calcium and phosphorus serum 
concentrations, or advanced age, which are all common risk fac-
tors associated with calcific aortic valve disease. The underlying 
pathophysiology of accelerated calcification in patients with RA 
is poorly understood with a paucity of literature or guidelines to 
guide management. Although data on valvular disease are scarce, 
there is published literature on increased rates of coronary artery 
calcification in this population, which may represent a shared 
etiology (15–18). Whether this is related to autoimmune disease 
severity over time or is increased in all patients with RA is a 
matter of continuing investigation. However, it is plausible that 
vascular inflammation may contribute to both valvular and coro-
nary artery changes by the same common mechanisms. Research 
now implicates osteogenic processes as key mechanism in calcific 
aortic valve disease and thereby providing two general directions 
for development of new therapies (1): inhibition of procalcific 
regulators and (2) induction of proresorptive regulators in aortic 
valve tissue (19, 20). However, tissue targeting may be essential to 
avoid damage to skeletal bone for example.
Calcific aortic valve disease commonly occurs in patients with 
bicuspid aortic valves (BAV). These patients present for AVR 
at a younger age and often have no concommittant obstructive 
coronary artery disease. It is estimated that up to 50% of patients 
requiring surgical AVR for severe aortic stenosis have BAV. 
Hemodynamic and developmental abnormalities of the congeni-
tal bicuspid aortic valve may predispose to premature calcification 
and valve failure, although no specific mechanisms have been 
reported. In contrast, patients with trileaflet aortic valve with severe 
calcification and stenosis present later in life for AVR (one decade 
later compared to BAV) and commonly share atherosclerotic risk 
factors, such as diabetes, chronic kidney disease, and increased 
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levels of oxidized LDL. Up to 60% of patients with trileaflet AV 
and severe stenosis require coronary artery bypass grafting for 
obstructive coronary artery disease, which is only required in up 
to 10% in patients with BAV and severe stenosis (21). However, 
cellular mechanisms leading to calcific aortic valve disease remain 
incompletely understood, and as demonstrated in this case, our 
patient has a trileaflet aortic valve, no coronary artery disease, and 
no other atherosclerotic risk factors beyond RA.
CoNCLUDING ReMaRKs
Taken together, the current guidelines do not support routine 
AVR in moderate AS not undergoing concomitant cardiac sur-
gery. Severe calcification alone in mild and moderate aortic ste-
nosis independently predicts the rate of disease progression and 
survival in these populations (20). Careful evaluation for other 
causes of LV dysfunction and symptoms should be undertaken 
in patients who do not meet standard criteria for AVR. In these 
patients with progressive symptoms and no other clear explana-
tion, the correction of a hemodynamic burden such as a calcified 
valve, even if only moderately severe when measured by mean 
aortic valve gradient, should be considered.
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